We demonstrate here that epithelial carcinoembryonic antigen (CEA)-related cell adhesion molecule-1 (CEA-CAM1) downregulation in prostate intraepithelial neoplasia (PIN) is inversely correlated with its upregulation in adjacent blood vessels. CEACAM1 silencing in prostate cancer cell line DU-145 via small interfering ribonucleic acid (siRNA) increased but its overexpression suppressed the expression of angiogenic/lymphangiogenic factors such as vascular endothelial growth factor (VEGF)-A, -C and -D, and angiogenic inhibitor collagen 18/ endostatin. Furthermore, CEACAM1 overexpression in DU-145 cells increased but CEACAM1 silencing reduced angiopoietin-1 expression. Inverse relation was found for angiopoietin-2. Supernatant of CEACAM1-overexpressing DU-145 suppressed but that of CEACAM1-silenced increased the VEGF-induced endothelial tubes. Electron microscopically the majority of PIN-associated blood vessels was structurally destabilized exhibiting endothelial fenestration, trans-and inter-endothelial gaps. In some PIN areas, invasion of single tumor cells into the destabilized blood vessels was observed. These data show that disappearance of epithelial CEACAM1 in PIN is accompanied by its upregulation in adjacent vasculature which apparently correlates with vascular destabilization and increased vascularization of prostate cancer. Strategies to either conserve the epithelial CEACAM1 or to target endothelial CEACAM1 might be useful for an anti-angiogenic therapy of prostate cancer.
Introduction
Tumor growth and metastasis essentially depend on a sufficient neovascularization via angiogenesis which is regulated by angiogenic activators and inhibitors (Hanahan and Folkman, 1996; Carmeliet, 2000) . We previously showed that soluble human carcinoembryonic antigen-related cell adhesion molecule-1 (CEA-CAM1), formerly known as biliary glycoprotein (BGP) or CD66a, exhibits angiogenic properties and functions as a morphogenic effector for vascular endothelial growth factor (VEGF) Wagener and Ergun, 2000) . CEACAM1 is expressed in the immature blood vessels of different tumors as well as in new vessels formed during physiological angiogenesis as it occurs in wound healing and endometrial proliferation Wagener and Ergun, 2000) CEACAM1 is a member of the carcinoembryonic antigen (CEA) family and can bind homophilically as well as heterophilically to the other CEA family members (Rojas et al., 1990) . Currently, 11 alternative splicing forms of the CEACAM1 gene are known (Kuroki et al., 1991; Barnett et al., 1993) . CEACAM1 is expressed in epithelia and leukocytes in addition to the endothelia of small angiogenic blood vessels. Furthermore, CEACAM1 is involved in the insulin clearance in the liver (Poy et al., 2002) . It was shown that CEACAM1 isoforms are expressed on the surface of Tcells upon activation and are involved in the regulation of Th1-mediated inflammation (Iijima et al., 2004) . Recently, we demonstrated the expression of CEA-CAM1 during angiogenic vascularization of human aortic valve stenosis (Chalajour et al., 2004) .
Downregulation of CEACAM1 at the mRNA expression level during tumorigenesis has been shown in several tumor types including hepatomas (Hixson et al., 1985) , carcinoma of colon (Neumaier et al., 1993; Nollau et al., 1997b) , endometrium (Bamberger et al., 1998) , breast (Riethdorf et al., 1997) and prostate (Nollau et al., 1997a; Lin and Pu 1999) . On the basis of such results, a tumor suppressive role for CEACAM1 has been postulated. Conformingly, CEACAM1 overexpression in different prostate cancer cell lines used in experimental tumor models in mice reduced tumor growth without affecting the proliferation of tumor cells themselves (Lin et al., 1991) . Furthermore, it has been reported that the tumor inhibitory function of CEACAM1 depends on the cis-determinants in its cytoplasmic domain (Izzi et al., 1999) . Additionally, CEACAM1 expression varies in proliferating and quiescent epithelial cells and this influences their proliferation (Singer et al., 2000) . CEACAM1 is colocalized and interacts with paxillin and integrin beta(3) (Ebrahimnejad et al., 2000; Brummer et al., 2001) , which are important for the formation of adhesion complexes and cell-matrix interactions.
Recently, it was shown that CEACAM1 overexpression in prostate cancer cell line DU-145 suppresses tumor angiogenesis by mechanisms that are yet unknown (Volpert et al., 2002) . To explore the role of CEACAM1 in the regulation of angiogenesis in prostate tissue, in particular, in prostate cancer, we first performed detailed immunohistochemical studies on human prostate cancer tissues to determine the exact tumor stage in which the epithelial CEACAM1 is clearly downregulated. Second, we determined the ratio between the CEACAM1 and CD34 positive blood vessels in normal prostate tissue in comparison to early prostate cancer prostate intraepithelial neoplasia (PIN). To mimic the CEACAM1 downregulation in the prostate glands containing high-grade PIN, we used CEACAM1 gene silencing via siRNA versus CEACAM1 overexpression in prostate cancer cell line DU-145 and determined the effect of CEACAM1 downregulation on the expression of angiogenesis regulating factors via quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analyses. The supernatants of CEACAM1-overexpressing versus CEACAM1-silenced DU-145 cells were used in in vitro endothelial tube assay. These analyses revealed that CEACAM1 silencing in DU-145 cells results in an increased endothelial tube formation in vitro. Finally, electron microscopic studies on PIN tissues showed endothelial fenestrations, transand/or inter-endothelial and basement membrane alterations in blood vessels adjacent to or localized within the wall of the PIN glands. In summary, we show here that CEACAM1 silencing in DU-145 cells, which mimics the epithelial downregulation of CEACAM1 in high-grade PIN, increases the expression of angiogenic and lymphangiogenic activators such as VEGF-A, -C, -D and angiopoietin-2 whereas angiopoietin-1 is downregulated. This is accompanied by CEACAM1 expression in endothelial cells of the angiogenically activated and structurally destabilized blood vessels and leads to an increased vascularization as it is observable in highgrade PIN areas.
Results
Epithelial CEACAM1 is downregulated but endothelial CEACAM1 is upregulated in PIN Immunostaining for CEACAM1 on sections of normal prostate tissue demonstrates the presence of CEACAM1 at the luminal surface of prostate glands ( Figure 1a ) but no staining is visible in the adjacent blood vessels which are visualized by immunostaining for CD34 (Figure 1b) . Immunostaining for CEACAM1 on prostate sections containing tissue areas with PIN showed no specific staining at the epithelial surface ( Figure 1c ) but a clear CEACAM1 staining in blood vessels adjacent to the PIN-containing glands. CD34 immunostaining on serial sections from the same area confirmed that approximately all blood vessels identified by CD34 (Figure 1d ) also exhibit CEACAM1 (Figure 1c) .
However, at the tumor stage Gleason 3, where tumor cells themselves form tubular/glandular structures, CEACAM1 was present at the luminal surface of these tubules (Figure 1e ) but the number of CEACAM1-positive blood vessels was markedly decreased. Only few blood vessels exhibited a weak CEACAM1 immunostaining ( Figure 1e ) when compared with the number of blood vessels identified by CD34 staining (Figure 1f ). In the tumor grade of Gleason 4 þ 5 or 5, where tumor cells are organized in solid cell clusters or cords, a major part of the small blood vessels exhibited CEACAM1 (Figure 1g ). In the control sections, as representatively shown here for the Gleason 5 tumor, there was no specific staining for CEACAM1 (Figure 1h ). The quantification of CEACAM1-positive and CD34-positive blood vessels was performed to determine the percentage of blood vessels exhibiting CEACAM1 in relation to the number of blood vessels marked by CD34 (Figure 1i ). In comparison to the normal areas of the same section, the relation of CEACAM1-positive to the whole number of blood vessels was the highest in PIN-area followed by that of solid tumor tissue.
CEACAM1 silence in DU-145 cells upregulates VEGF-A, -C, -D, angiopoietin-2 and collagen 18 but downregulates angiopoietin-1 To determine whether and how the presence of CEACAM1 or its downregulation in prostate epithelia as it occurs in PIN influence the expression of angiogenic factors, we used the overexpression versus gene silencing via siRNA technique in prostate cancer cell line DU-145 with subsequent RNA extraction and real-time RT-PCR analyses. To monitor the effectiveness of CEACAM1 overexpression versus silencing in DU-145, we measured the CEACAM1 expression at the mRNA-level by real-time RT-PCR as well as at the protein level via Western blot (Figure 2a -c; Supplementary information). These studies showed that our human CEACAM1-specific siRNAs could reduce the basal expression of CEACAM1 by three times (Figure 2a ) in comparison to the control siRNA. In comparison to empty vector transfection, the overexpression of CEA-CAM1 resulted in an increase of CEACAM1 mRNA by more than 9 Â 10 4 times (Figure 2b ). These results were confirmed by Western blot analyses showing a significant decrease of CEACAM1 protein level when DU-145 cells were co-transfected with CEACAM1-expression vector pcDN A3.1/CEACAM1 and CEACAM1-specific siRNA (Figure 2c ). Similar results were obtained using the CEACAM1 antibodies T84.1 and human goat CEACAM1 antibody from R&D Systems (Supplementary Information). (Figure 2d , f, h, j and n) but increases the expression of Ang1 (Figure 2l ). In comparison to the siRNA for luciferase used as control, CEACAM1 silencing upregulates VEGF-A, -C, -D, collagen 18 and Ang2 (Figure 2e , g, i, k and o) but decreases the expression of Ang1 significantly (Figure 2m ).
CEACAM1 downregulation in PIN is accompanied by an increase of VEGF in situ To confirm the data obtained by quantitative real-time RT-PCR, we performed double immunostaining for CEACAM1 and VEGF on paraffin sections of prostate tissue containing areas with normal and different stages of prostate cancer and PIN. In the normal prostate glands CEACAM1 was found at the luminal surface of the epithelium as expected (Figure 3a) . In such glands, a weak staining for VEGF was detected in the epithelial cells, almost in an equal amount (Figure 3a) , whereas a strong VEGF staining was present in some interstitial stromal cells. In comparison to the normal glands, the pattern of VEGF staining was changed markedly in high-grade PIN. A considerable enhancement of VEGF staining was found at that part of the PIN epithelium where CEACAM1 was clearly downregulated or disappeared completely (Figure 3b ). No such a relation between CEACAM1 and VEGF expression was found in the tubules of the Gleason 3 tumors (Figure 3c ). CEACAM1 was present at the luminal surface and some single tumor cells exhibited a strong VEGF staining ( Figure 3c ). In contrast, in Gleason 4 þ 3 or 4 þ 5 tumors, where tumor cells form more irregular tubules or solid cell cords, CEACAM1 staining was not present in tumor cells but in a part of the tumor blood vessels (Figure 3d ). In these cases, a high number of tumor cells exhibited a strong VEGF staining. In the control sections no specific staining was found, neither for VEGF nor for CEACAM1 (not shown).
CEACAM1 downregulation in PIN is accompanied by destabilization of the vascular wall One of the common phenotypes of angiogenicly activated blood vessels is the structural destabilization of the vascular wall such as endothelial fenestration, opening of inter-endothelial contacts, basement membrane degradation and detachment of pericytes from the endothelial layer. To determine whether the switch of CEACAM1 expression such as epithelial downregulation but endothelial upregulation in high-grade PIN does have any relation to the vascular structure, we Figure 1 (a-h) Expression pattern of carcinoembryonic antigen (CEA)-related cell adhesion molecule-1 (CEACAM1) in normal prostate and prostate cancer tissue. In normal prostate, CEA-CAM1 is visible at the luminal surface of the prostate epithelium using the antibody 4D1/C2 (a) but not in the adjacent blood vessels visualized by CD34-staining on a serial section from the same area (b). In high-grade prostate intraepithelial neoplasia (PIN) the epithelial CEACAM1 is almost disappeared while the majority of the adjacent blood vessels (c) exhibits CEACAM1 when compared with the immunostaining for the endothelial marker CD34 on the serial section (d). In Gleason 3 prostate cancer, where tumor cells themselves form glandular structures, CEACAM1 is present at the luminal surface of tumor glands (e) and only a part of the blood vessels exhibit a weak CEACAM1 staining (arrows) (e) as confirmed by CD34 staining on the serial section (f). Also in solid prostate cancer of the stages Gleason 4 þ 5 a part of the tumor vessels exhibits CEACAM1 but there is no CEACAM1 staining in tumor cells (g). In the control section treated only with the secondary antibody no specific staining is visible (h). All sections are counterstained with calcium red. (a-h): Â 450. The percentage of CEACAM1-positive blood vessels in relation to CD34-positive vessels switches from 13.4% in the normal area with epithelial presence of CEACAM1 to 78.4% in the PIN areas and to 50.8% in the solid tumor area (i) where the epithelial CEACAM1 was disappeared.
CEACAM1 and angiogenic switch in prostate cancer D Tilki et al performed electron microscopic studies. Normal prostate ( Figure 4a ) and high-grade PIN (Figure 4b ) tissue areas were first identified by light microscopic evaluation of semi-thin sections. Electron microscopic evaluation of such tissue areas revealed clear structural changes in PIN-associated blood vessels when compared with those of normal tissue. A continuous endothelial lining, regularly constructed inter-endothelial junctions visible as electron dense zones, a regular structured basement membrane, and tightly assembled pericyte processes were found in the wall of all blood vessels of normal prostate tissue ( Figure 4c ). Higher magnifications showed basal lamina and inter-endothelial contacts in a regular structure (Figure 4d ). In all analyses of normal prostate tissue a regular integration of pericyte processes into the vascular wall, as they were embedded in the same basal lamina as endothelial cells, was observed. . Western blot analysis using the CEACAM1-antibody 4D1/C2 shows that the enhanced CEACAM1 protein expression is significantly reduced when DU-145 cells were co-transfected with CEACAM1 expression vector pcDNA3.1/CEACAM1 plus CEACAM1-small interfering ribonucleic acid (siRNA) (c), which shows the specificity and efficiency of the CEACAM1-siRNA. Also the weak basal expression of CEACAM1 at the protein level (empty vector) disappears completely by CEACAM1 silence. Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analyses demonstrate that CEACAM1 overexpression suppresses but CEACAM1 silencing increases the expression of potent angiogenic and lymphangiogenic factors such as VEGF-A (d-e), VEGF-C (f-g), VEGF-D (h-i), and the expression of collagen 18 (j-k), the maternal substance of the angiogenesis inhibitor endostatin. In contrast, the expression of Ang1 is increased by CEACAM1 overexpression but significantly decreased by CEACAM1 silencing (l-m). Inversely to Ang1, the expression of Ang2, the naturally occurring antagonist of Ang1, is suppressed by CEACAM1 overexpression, but enhanced by CEACAM1 silencing in DU-145 cells (n-o).
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In comparison to the normal vasculature, electron microscopic studies of PIN tissue areas revealed that approximately more than 80% of small blood vessels adjacent to the PIN glands are structurally destabilized showing either extensive endothelial fenestrations (Figure 4e and f) and/or disruption of inter-endothelial contacts resulting in distraction of endothelial processes from each other (Figure 4g) . Remarkably, such alterations of the vascular structure were observed almost at the sides of the vascular wall faced towards the dysplastic PIN epithelium (Figure 4f and g ). In such areas of the vascular wall, there was only a degraded basal lamina between blood vessels and dysplastic PIN epithelium (Figure 4g ). Occasionally, we found invasion of dysplastic cells into such destabilized blood vessels (Figure 4h ).
CEACAM-1 silencing in DU-145 cells increases the endothelial migration in in vitro wound assay Using the supernatants of CEACAM1-overexpressing versus CEACAM1-silenced DU-145, cells we performed in vitro wound assay to study the effect of epithelial CEACAM1 on VEGF-induced endothelial migration. The wound distance, which describes the distance between both edges of the wounded area, was measured as quantification parameter. In comparison to the supernatant of empty vector-transfected DU-145 cells plus VEGF (Figure 5a ) the wound distance remained on normal prostate tissue demonstrate CEACAM1 at the luminal surface (arrowheads) as expected and VEGF staining in the cytoplasm of epithelial cells as well as in the interstitial myocytes (arrows) (a). In prostate glands containing prostate intraepithelial neoplasia (PIN), CEACAM1 is partially downregulated or disappeared completely (arrowheads) but is concurrently upregulated in the adjacent blood vessels (arrows) (b). At these sites of CEACAM1 downregulation, a clearly increased VEGF staining is detectable (b). In Gleason 3, CEACAM1 and VEGF are present in a part of the tumor epithelial cells (c) whereas small blood vessels also exhibit CEACAM1 (arrows). Note that in contrast to the normal prostate glands (a) in glands of Gleason 3 CEACAM1 is present not only at the luminal surface but also at the basal-lateral sides of tumor epithelial cells (c). In the higher stages of prostate cancer, as demonstrated here by Gleason 4 þ 5, CEACAM1 is present in the small blood vessels (arrows) but not in tumor cells whereas a strong VEGF staining is found in a part of the tumor cells (d). Pst: prostate stone. Â 450. Figure 4 (a-h) Structural destabilization of blood vessels adjacent to prostate intraepithelial neoplasia (PIN): in semithin sections (1 mm thick) of Epon-embedded human prostate tissue, normal (a) and PIN (b) areas are identified by light microscopic evaluation. From such areas, fine sections (80 nm thick) are cut and studied by electron microscopy. Capillaries (Cap) adjacent to the normal epithelium (Ep) (c) show a normal structure including regularly structured inter-endothelial contacts (arrowhead) and basal lamina is visible on the presence of lamina densa (arrow) as shown in higher magnification (d). Capillaries adjacent to the PIN glands or within the wall of the PIN glands show extensive endothelial fenestration (arrowheads) (e and insert in higher magnification in e). Such extensive fenestration (arrowheads) is mostly present at that part of the capillary wall (Cap), which is almost faced towards the dysplastic PIN epithelium (PIN-Ep) (f). Also large interendothelial gaps (arrowhead) are observed in capillaries (Cap) within the wall of PIN glands (g). Note, that the basal lamina between PIN epithelium and capillaries show a diffuse structure without a clearly recognizable lamina densa indicating a degradation of vascular as well as epithelial basement membrane (f and g). Occasionally, tumor cell invasion into destabilized blood vessels within the wall of PIN glands is found (h). (a-b) Â 550, (c) Â 4500, (d) Â 12,000, (e, f and h) Â 8500, insert in (e) Â 16,500, (g) Â 10,500.
CEACAM1 and angiogenic switch in prostate cancer D Tilki et al approximately two times larger after the combined application of VEGF and the supernatant of CEA-CAM1-overexpressing DU-145 (Figure 5b ). Note that the migration induced by the combined application of the supernatant of luciferase-silenced DU-145 cells plus VEGF (Figure 5c ) was almost comparable to that induced by VEGF plus the supernatant of empty vectortransfected DU-145 cells. In contrast, the wound distance was significantly reduced after application of VEGF plus the supernatant of CEACAM1-silenced DU-145 cells (Figure 5d ), by nearly three times in comparison to CEACAM1 overexpression and by two times in comparison to supernatant of empty vectortransfected or luciferase-silenced DU-145 cells.
CEACAM1 overexpression in DU-145 cells suppresses but its silencing increases endothelial tube formation in vitro To determine the potential effects of epithelial presence of CEACAM1 on the blood vessel morphogenesis, we used the supernatants of CEACAM1-overexpressing versus CEACAM1-silenced DU-145 cells in in vitro endothelial tube assay using collagen gel. The number of VEGF-induced endothelial tubes (Figure 6a ) was significantly reduced when VEGF plus supernatant of CEACAM1-overexpressing DU-145 cells were applied (Figure 6b ). The supernatant of CEACAM1-overexpressing DU-145 cells alone did not cause any tube formation (not shown). In contrast, the application of CEACAM1-silenced DU-145 cells alone induced endothelial tubes (Figure 6c ), but less than VEGF alone. Correspondingly, VEGF plus the supernatant of CEA-CAM1-silenced DU-145 cells enhanced the number, the network, and the branching pattern of endothelial tubes (Figure 6d ). No significant changes in tube formation were seen, when VEGF plus supernatant of luciferasesilenced DU-145 cells were applied (Figure 6e ). In the controls, where endothelial cells have only been treated with basal medium, no tubes were found (Figure 6f ).
Discussion
The present results show that the CEA-related cell adhesion molecule CEACAM1, which is present at the luminal surface of normal prostate epithelium, is Busch et al. (2002) , but the current work focuses on the early stage of prostate cancer, the PIN. High-grade PIN is considered to be a noninvasive precancerous form of prostate cancer (Mazzucchelli et al., 2000) and is associated with an increase in vascular density suggesting an activation of angiogenesis in this precancerous stage of prostate tumor (Mazzucchelli et al., 2000; Huss et al., 2001) . To achieve insights into the CEACAM1-induced mechanisms in the angiogenesis in prostate cancer we used overexpression versus silencing of CEACAM1 in the prostate cancer cell line DU-145. Although it was previously reported that DU-145 cells do not express CD66a (CEACAM1) endogenously using the RNAse protections assay (Luo et al., 1999) we found a clear CEACAM1 transcript in wild type DU-145 cells using quantitative RT-PCR as well as regular PCR (Supplementary information). CEACAM1 presence at the luminal surface of normal prostate epithelium is apparently involved in the signalling of molecules and factors regulating angiogenesis as shown here by suppressed expression of VEGF-A, -C, -D and Ang2 after CEACAM1 overexpression in DU-145. In contrast, CEACAM1 gene silencing in these cells results in an upregulation of the mentioned factors and activates endothelial tube formation in vitro. The findings regarding the expression of VEGF-C and VEGF-D after CEACAM1 silencing in DU-145 cells are in line with our recently published data obtained from bladder cancer cell lines (Oliveira-Ferrer et al., 2004) but the data regarding VEGF-A and in particular regarding Ang1 and Ang2 are new findings in DU-145. This may reflect differences in the CEACAM1 signalling depending on cancer type. Whereas the activation of endothelial migration and tube formation by CEA-CAM1 silencing can be explained by increased level of the pro-angiogenic factors mentioned above, the suppression of VEGF-induced endothelial migration and tube formation by CEACAM1 overexpression suggest an increased presence of angiogenic inhibitors which are yet unidentified. The surprising suppression of collagen 18/endostatin by CEACAM1 overexpression in DU-145 cells supports the hypothesis regarding the presence of additional, but unidentified angiogenesis inhibitors. These data are partially in line with a recent publication showing that CEACAM1 overexpression inhibits the growth of experimental prostate cancer by suppression of angiogenesis (Volpert et al., 2002) . Our findings show in agreement with this paper that CEACAM1 overexpression in DU-145 cells suppresses angiogenesis in vitro but we show for the first time that this effect may partially be mediated by decreased expression of potent pro-angiogenic factors in addition to a potential existence of unknown inhibitors. This interpretation is further supported by our findings resulting by CEA-CAM1 silencing in DU-145 cells which inverses the suppressive effect of CEACAM1 overexpression.
The concurrent upregulation of CEACAM1 in endothelial cells of blood vessels adjacent to the PIN glands suggests a direct involvement of CEACAM1 in the early vascularization of prostate cancer. These data are supported by our previous findings showing an upregulation of CEACAM1 in endothelial cells after their stimulation by VEGF and the functioning of CEACAM1 as a morphogenetic co-factor for VEGF during capillary formation in vitro, and increased expression in small tumor blood vessels including those of prostate cancer . Additionally, it was shown that CEACAM1 was enriched in tumor endothelial cells compared with whole lung tumor tissue using a subtracting proteomic mapping technique (Oh et al., 2004) . Interestingly, our recent data demonstrate that CEACAM1 overexpression in human micro vascular endothelial cells leads to a significant upregulation of VEGF expression among other pro-angiogenic factors such as Ang1, Ang2, angiogenin and IL-8 (Kilic et al., 2005) . This signalling switches endothelial cells to an angiogenic phenotype and demonstrates an inverse action of endothelial CEACAM1 in comparison to epithelial CEACAM1 signalling as demonstrated here by the overexpression of CEACAM1 in the prostate cancer cell line DU-145. The interplay of these both contrary signalling mechanisms induced by epithelial versus endothelial CEACAM1 seems to be essentially involved in the increase of PIN vascularization and prostate cancer invasion. Indeed, bringing the activation of angiogenesis into focus, the present data demonstrate that CEACAM1 downregulation in PIN acts synergistically with the CEACAM1 upregulation in endothelial cells of adjacent blood vessels. Both lead to an enhancement of VEGF-A, -C, -D and Ang2 and to an activation of angiogenesis.
This interpretation is also supported by our electron microscopic findings, showing a clear structural destabilization of blood vessels adjacent to PIN such as extensive endothelial fenestrations, large inter-endothelial gaps, and basement membrane degradation. Both, the epithelial downregulation and the endothelial upregulation of CEACAM1 may induce the structural changes of the prostate blood vessels presented here via upregulation of VEGF-A, -C and -D. As it is known CEACAM1 and angiogenic switch in prostate cancer D Tilki et al these factors lead to an increase of vascular permeability (Roberts and Palade, 1995; Saaristo et al., 2002; McDonald and Choyke, 2003; Cao et al., 2004) . Together with the upregulation of Ang2 but downregulation of Ang1 by CEACAM1 silencing in DU-145 cells, these data implicate that the CEACAM1 downregulation in prostate epithelium is involved in a cascade of reactions leading to structural destabilization of adjacent blood vessels and subsequent angiogenic activation.
An additional interesting aspect of CEACAM1 signalling evidenced here is the upregulation of factors which are known to lead to lymphangiogenesis (Alitalo and Carmeliet, 2002; Cao et al., 2004) such as VEGF-C and -D after CEACAM1 silencing in DU-145 cells. Lymphangiogenesis represents an additional way mediating the spreading of tumor cells and tumor metastasis via lymphatics. Whether and how CEACAM1 is involved in the lymphangiogenesis is yet unknown and cannot be addressed at this time. Detailed preliminary studies in our lab show that CEACAM1 is indeed detectable in lymphatics adjacent to tumor cell groups or to structures containing early tumor cells such as CIS of testis, superficial tumors of urinary bladder or PIN. These data demonstrate an increased expression of CEACAM1 in tumor lymphatics prior to angiogenic activation (Kilic et al., in preparation) . Recently, CEACAM1 was found to be upregulated in endothelial cells during the lymphatic reprogramming of blood vascular endothelium (Hong et al., 2004) . However, additional in vitro and in vivo studies are needed to determine the possible role of CEACAM1 in lymphangiogenesis.
Taken together, we demonstrate here that the downregulation of CEACAM1 in prostate epithelial cells as it occurs in PIN and in Gleason 4 or 5 prostate cancer induces an angiogenic signalling which increases the expression of VEGF-A, -C, -D and Ang2 but decreases the expression of Ang1 (Figure 7 ). This is accompanied by vascular destabilization indicating activation of angiogenesis. Indeed, the supernatant of the CEA-CAM1-silenced DU-145 induces endothelial tubes and potentates the VEGF-induced endothelial tube formation. Finally, the upregulation of CEACAM1 in endothelial cells of blood vessels adjacent to PIN accompanied with the epithelial CEACAM1 downregulation in high-grade PIN apparently acts proangiogenic and sustains the vascularization of PINsurrounding tissue and solid prostate cancer tissue. Figure 7 Inverse role of carcinoembryonic antigen (CEA)-related cell adhesion molecule-1 (CEACAM1) in the regulation of angiogenesis in prostate cancer: the presence of CEACAM1 in the normal prostate epithelium suppresses the expression of potent angiogenic factors such as vascular endothelial growth factor (VEGF)-A, -C, and -D and Ang2 but increases the expression of Ang1, the natural Ang2 antagonist. Via this mechanism CEACAM1 may be involved in the maintenance of vascular stability and integrity, a process probably preventing the angiogenic switch. CEACAM1 downregulation, as it occurs in prostate intraepithelial neoplasia (PIN), is obviously accompanied by an upregulation of angiogenic factors mentioned above but by a downregulation of Ang1. Concurrently, CEACAM1 is upregulated in endothelial cells of angiogenicly activated blood vessels adjacent to PIN. This switch is apparently accompanied by vascular destabilization, a process marking the initiation of angiogenesis. In summary, CEACAM1 seems to play a dual role in the regulation of angiogenesis depending on which cell type is expressing it. While epithelial presence of CEACAM1 functions inverse to the endothelial expression of CEACAM1, the epithelial downregulation but the concurrent endothelial upregulation act synergistically and promote angiogenesis, tumor vascularization, and probably tumor invasion.
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Materials and methods

Tissue samples
Normal tissue samples (n ¼ 5) from human prostate were obtained after the surgical removal of the prostate because of a bladder tumor (cystoprostatectomy specimens). Formalinfixed and paraffin-embedded tissue blocks of human prostate cancer (n ¼ 15) were provided from the Department of Pathology of the University Hospital Hamburg-Eppendorf. Additionally, in five cases prostate cancer tissue samples were fixed in Bouin's solution and then embedded in paraffin. The paraffin tissue blocks were sectioned and used for immunohistochemistry as described below.
Cell culture
Commercially available human prostate cancer cell line DU-145 (DKFZ, Tumorbank, Heidelberg, Germany) was cultured on gelatine coated dishes in RPMI 1640 medium containing 25 mM HEPES Buffer with L-Glutamin (Gibco, Germany), 10% FBS (fetal bovine serum), 1% Glutamin, 1% Penicillin/ Streptomycin, and 1 mM sodium pyruvate (Invitrogen, CA, USA). Cells were cultured in RPMI 1640 Medium in six-well cluster dishes in the same medium until 70% confluence. They were then used for transfection either for CEACAM1 overexpression or for CEACAM1 gene silencing as described below. HDMEC (human dermal microvascular endothelial cells) supplied from PromoCell (Heidelberg, Germany) were grown in MV medium containing 5% FCS. All cells were cultured at 371C in 5% CO 2 /95% air.
CEACAM1 overexpression versus CEACAM1 silencing in prostate cancer cell line DU-145
To overexpress the CEACAM1 in the prostate cancer cell line DU-145 we used the pcDNA3.1/Hygro(-)plasmid. (Clontech, CA, USA) in which the cDNA encoding full-length CEA-CAM1 was ligated and designated it as pcDNA3.1/CEA-CAM1. For CEACAM1 silencing, we used the siRNA technique. The target regions for the siRNA sequences were selected from the cDNA of CEACAM1 according to the guidelines described by Elbashir et al. (2002) . The following targeted cDNA sequences for CEACAM1 silence and target sequence for firefly luciferase silence as negative control have recently been established in our lab (Oliveira-Ferrer et al., 2004) : Targeted sequence (cDNA) TS152: 5 0 AACCTTCTGG AACCCGCCCAC, and targeted sequence (cDNA) TS210: 5 0 AATGTTGCAGAGGGGAAGGAG. Target sequence (cDNA): 5 0 AACGTACGCGGAATACTTCGA from the firefly luciferase gene was chosen as a control for CEACAM1 silencing studies. The preparation of siRNA duplexes was performed using The Silencert siRNA Construction Kit (Ambion Inc., TX, USA). From cell lysates, proteins were extracted and used in SDS-PAGE and immunoblotting.
Quantitative reverse transcriptase-polymerase chain reaction analyses Total cellular RNA from 5 Â 10 6 prostate cancer cells (prostate cancer cell line DU-145) was extracted using Trizol Reagent (Gibco) following the manufacture's protocol. Using the YouPrime First-Strand cDNA synthesis kit (Amersham-Pharmacia, Freiburg, Germany) 3 mg of total RNA each were reversetranscribed into cDNA. Reverse transcriptase-polymerase chain reaction was carried out on LightCycler Instrument (Roche, Basel, Switzerland) using the fluorescent dye SYBR Green for relative quantification. The relative amount of the analysed genes in the samples was calculated from a standard curve obtained by plotting four known input concentrations of plasmid containing the gene to be analysed (log dilutions) to the PCR cycle number (Crossing Point, CP) at which a significant increase in fluorescence was detected. The data of two independent analyses for each gene and sample or plasmid dilution were averaged. The calculated amount of each factor in the samples was normalized to the housekeeping gene glyceraldehyde phosphate dehydrogenase (GAPDH).
Western blot analyses
Western blot analyses were performed using three different CEACAM1 antibodies, the monoclonal antibodies 4D1/C2 and T84.1 and the polyclonal antibody (R&D System, Germany). Total protein concentration was determined via BCA Kit (Pierce, Rockford, IL, USA) and controlled via detection of vimentin as housekeeping protein. Protein extracts (20 mg total protein) of empty vector-transfected and of CEACAM1-overexpressing versus -silenced and luciferasesilenced DU-145 cells were separated in 8% SDS-PAGE and transferred to the nitrocellulose membrane. The detection of CEACAM1 via immunoblotting was used to determine the effectiveness of CEACAM1 overexpression versus CEACAM1 silencing on the protein level prior to the use of the supernatants of these cells in mechanistic angiogenesis assays and before their use for RNA extraction with subsequent quantative RT-PCR analyses. The bands were visualized by enhanced chemiluminescence detection using ECL reagents supplied by Amersham (Braunschweig, Germany).
Immunohistochemistry
Immunohistochemical staining for CEACAM1 was performed on paraffin-embedded tissue sections obtained from normal human prostate tissue (n ¼ 5) and prostate cancer tissues (n ¼ 15) containing different stages of prostate cancer, such as PIN and Gleason 3 to 5 as well as areas of normal prostate glands. Tissue specimens were fixed in 4% formaldehyde (24 h) at room temperature and further processed for embedding in paraffin. After the histological determination of tumor stages, immunostaining using the human CEACAM1-specific antibody 4D1/C2 was performed as described recently Wagener and Ergun 2000) . Blood vessels were visualized using the monoclonal CD34 and CD31 (PECAM1) antibodies (final dilution 1:50) (DAKO, Denmark). Controls were performed as described recently. After development of the immunostaining for CEACAM1 and CD34 on serial sections, the CD34-positive and CEACAM1-positive blood vessels closely adjacent to the normal prostate gland, to the glands with high-grade dysplasia PIN and to the tubular structures formed by cancer cells of prostate cancer stage Gleason 3 were counted separately. Afterwards, the ratio between CEACAM1-positive blood vessels and those positive for CD34 was determined.
Light and electron microscopic analyses
To analyse the vascular structure light-and electron-microscopically, in seven cases prostate tissue pieces were fixed in phosphate-buffered glutaraldehyde (5.5%) for 18 h immediately after surgical removal. These tissue pieces were embedded in Epon 812, cut in semithin sections (1 mm thick), and stained by Toluidin blue/Pyronin (Ergun et al., 1996; Kilic and Ergun 2001) . Light microscopic (Leica, DM/LB) evaluation was performed to identify prostate tissue areas of normal, PIN and prostate cancer of different stages. Digital photographs from the sections were taken via a digital camera (Leica, DC 100, Bensheim, Germany). Afterwards, for electron microscopic studies, fine sections (80 nm) were cut from the light microscopically marked areas of epon-embedded tissue blocks and contrasted by uranyl acetate (Merk, Germany) and lead citrate (Merk, Germany). The electron microscope was a Philips EM 300 (Ergun et al., 1996; Kilic and Ergun, 2001 ).
In vitro wound assay HDMECs were cultivated in 48-well cluster tissue culture plate until they reached confluence. In the middle of each well a wound line was induced using a pipette. Then, they were treated with VEGF alone, conditioned media of CEACAM1-overexpressing versus CEACAM1-silenced DU-145 cells alone, VEGF plus conditioned media of CEACAM1-overexpressing and VEGF plus conditioned media of CEACAM1-silenced DU-145 cells. Conditioned media of empty vector transfected and of luciferase-silenced DU-145 cells alone or in combination with VEGF were used as control. The wounding area of each well was observed by phase contrast microscopy (Zeiss, Jena, Germany). These areas were observed daily and photographed via a digital camera (Zeiss, Jena, Germany) mounted on the phase contrast microscope. The wounding distance was measured using the morphometric program Optimas (Optimast, Seattle, USA).
In vitro endothelial tube formation assay This assay was carried out using three-dimensional type I collagen gel (Vitrogen 100, Collagen Corp., CA, USA) which were prepared in 48-well cluster tissue culture dishes (Costar, Cambridge, MA, USA) as previously described (Ergun et al., 1996; Kilic and Ergun, 2001) . After polymerization of the gel at 371C, HDMECs were seeded onto the solidified gels at a concentration of 2 Â 10 4 /well in 300 ml of MV medium (Promocell, Heidelberg, Germany) containing 5% FCS. At confluence, the medium was replaced by basal medium containing 5% FCS without further supplements. After 24 h, the supernatants of CEACAM1 overexpressing versus silencing DU-145 cells as well as that of cells transfected with empty vector or with the siRNA of luciferase were added individually or in combination with VEGF165. These parameters have been renewed after 3 days and photographs were taken by phase contrast microscopy (Zeiss, Jena, Germany). The measurements of tubular length were performed using the morphometric program Optimas (Optimast, Seattle, USA).
